Daehan New Pharm Co Ltd
KOSDAQ:054670
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6 290
8 380
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
D
|
Daehan New Pharm Co Ltd
KOSDAQ:054670
|
92.4B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
524.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
274.5B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
206.8B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.2B USD |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
Daehan New Pharm Co Ltd
Glance View
Daehan New Pharm Co., Ltd. engages in the production of pharmaceuticals and animal health goods. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2002-02-26. The firm provides two categories of products: human pharmaceutical products and animal pharmaceutical products. Its human pharmaceutical products include analgesics, anti-inflammatory drugs, antipyretics, antibacterial, antidiabetics, antihistamines, antineoplastics, immunosuppressants, cardiovascular drugs, gastrointestinal drugs, muscle relaxants, antispasmodics and others. Its animal pharmaceutical products include antibacterial, coccidiostats, antihelmintics, probiotic, nutrients, metabolic stimulants, disinfectants, functional supplement feeds, liver tonics, antihelmintics and others for poultries, cattle, sheep, swine and fishes.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Daehan New Pharm Co Ltd is 6.5%, which is below its 3-year median of 9.9%.
Over the last 3 years, Daehan New Pharm Co Ltd’s Operating Margin has decreased from 13.7% to 6.5%. During this period, it reached a low of 6.5% on Oct 30, 2025 and a high of 13.9% on Dec 31, 2022.